Invega, known generically as paliperidone, is an atypical antipsychotic medication that is not FDA-approved for the treatment of depression [1]. It is primarily prescribed for schizophrenia and schizoaffective disorder [1].
What is Invega used for?
Invega (paliperidone) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults and adolescents 12 years of age and older [1]. It is also indicated for the treatment of schizoaffective disorder in adults [1]. These conditions are characterized by symptoms such as hallucinations, delusions, disorganized thinking, and changes in mood and behavior.
Can Invega be used off-label for depression?
While not officially approved for depression, some physicians may consider prescribing Invega off-label in specific circumstances, particularly if depression is part of a broader mental health condition like schizoaffective disorder or if a patient has not responded to other treatments [2]. Off-label prescribing means a drug is used for a condition or in a way not specified in its FDA approval [3].
How does Invega work?
Invega is thought to exert its effects by blocking dopamine and serotonin receptors in the brain [1]. These neurotransmitters play a crucial role in regulating mood, cognition, and perception. By altering the activity of these receptors, Invega aims to help manage the symptoms associated with schizophrenia and schizoaffective disorder.
What are the side effects of Invega?
Common side effects associated with Invega include drowsiness, dizziness, weight gain, increased prolactin levels, and movement disorders like parkinsonism or tardive dyskinesia [1]. Less common but serious side effects can include neuroleptic malignant syndrome, a potentially fatal condition, and metabolic changes such as hyperglycemia and dyslipidemia [1].
When might Invega be considered for depression-like symptoms?
Invega might be considered for patients experiencing depression as a component of schizoaffective disorder, which involves symptoms of both schizophrenia and a mood disorder, such as depression or bipolar disorder [1]. In cases of treatment-resistant schizophrenia where mood symptoms, including depression, are prominent, an antipsychotic like Invega might be part of a treatment plan [2].
Are there alternatives to Invega for depression?
For unipolar depression, established treatments include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) [4]. Psychotherapy, such as cognitive behavioral therapy (CBT), is also a primary treatment for depression [4]. Electroconvulsive therapy (ECT) may be used for severe or treatment-resistant depression [4].
What is the patent status of Invega?
Information regarding the patent status and exclusivity of Invega can be found on drug patent tracking websites [5]. These resources detail patent expiration dates and market exclusivity periods, which are crucial for understanding when generic versions of the drug may become available.
Who manufactures Invega?
Invega is manufactured by Janssen, a pharmaceutical company that is part of Johnson & Johnson [1].
Sources:
[1] https://www.janssen.com/
[2] https://www.ncbi.nlm.nih.gov/
[3] https://www.fda.gov/
[4] https://www.nimh.nih.gov/
[5] https://drugpatentwatch.com/